v3.26.1
Acquisitions, Research Collaborations and Licensing Agreements (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2026
Jun. 30, 2026
May 31, 2026
Jan. 31, 2026
Mar. 31, 2025
Dec. 31, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
May 31, 2025
Business Combination [Line Items]                        
Charges for research and development asset acquisitions                 $ 13,811.0 $ 0.0    
Research and development             $ 9,741.0 $ 4,048.0 22,333.0 7,669.0    
Property, plant and equipment, net   $ 25,737.0         25,737.0   25,737.0   $ 25,316.0  
TARGAN                        
Business Combination [Line Items]                        
Unrealized gain on investments             71.0   71.0      
Subsequent Event | TARGAN                        
Business Combination [Line Items]                        
Business combination, consideration transferred $ 650.0                      
Peloton Therapeutics, Inc.                        
Business Combination [Line Items]                        
Current liability   50.0         50.0   50.0      
Non-current liability   100.0         100.0   100.0      
Maximum aggregate sales-based milestone payments   900.0         900.0   900.0      
Peloton Therapeutics, Inc. | Welireg                        
Business Combination [Line Items]                        
Increase in intangible asset   192.0                    
Cumulative amortization expense             65.0   65.0      
Terns Pharmaceuticals, Inc.                        
Business Combination [Line Items]                        
Consideration transferred, asset acquisition     $ 6,800.0                  
Payments to settle share-based equity awards     606.0                  
Asset acquisition, consideration transferred, settlement of unvested share-based payment awards     $ 433.0                  
Charges for research and development asset acquisitions             5,700.0          
Net assets acquired   1,100.0         1,100.0   1,100.0      
Cash and cash equivalents   505.0         505.0   505.0      
Asset acquisition, investments   487.0         487.0   487.0      
Deferred tax assets   190.0         190.0   190.0      
Net liabilities, other   105.0         105.0   105.0      
Cidara Therapeutics, Inc.                        
Business Combination [Line Items]                        
Maximum aggregate sales-based milestone payments       $ 455.0                
Consideration transferred, asset acquisition       9,200.0                
Payments to settle share-based equity awards       570.0                
Asset acquisition, consideration transferred, settlement of unvested share-based payment awards       406.0                
Charges for research and development asset acquisitions                 9,000.0      
Net assets acquired   332.0         332.0   332.0      
Future regulatory milestone payments (up to)       $ 105.0                
sac-TMT                        
Business Combination [Line Items]                        
Research and development arrangement, contract to perform for others, compensation earned             200.0   400.0      
Research and development arrangement receivable   $ 400.0         $ 400.0   $ 400.0      
sac-TMT | Forecast                        
Business Combination [Line Items]                        
Research and development arrangement, contract to perform for others, compensation earned           $ 700.0            
HRS-5346 , Jiangsu Hengrui Pharmaceuticals Co., Ltd.                        
Business Combination [Line Items]                        
Research and development               $ 200.0   $ 200.0    
Jiangsu Hengrui Pharmaceuticals Co., Ltd.                        
Business Combination [Line Items]                        
Maximum aggregate sales-based milestone payments                       $ 1,500.0
Future regulatory milestone payments (up to)                       177.5
Future contingent developmental milestone payments (up to)                       $ 92.5
WuXi Vaccines' facility                        
Business Combination [Line Items]                        
Consideration transferred, asset acquisition         $ 437.0              
WuXi Vaccines' facility | Asset under Construction                        
Business Combination [Line Items]                        
Property, plant and equipment, net         $ 759.0